Informations générales (source: ClinicalTrials.gov)
A Study to Collect Patients, Medical, and Biological Data From Patients Being Treated for Metastatic Colorectal Cancer With a Specific Genetic Mutation: BRAFV600E (COBRAF)
Interventional
N/A
UNICANCER (Voir sur ClinicalTrials)
juillet 2023
juillet 2028
14 décembre 2024
The study will be conducted in patients with metastatic colorectal cancer (mCRC)
harboring a BRAFV600E mutation, to collect clinical data and biological samples to be
used for research but also to gather real-world clinical data concerning the treatments
and the survival outcomes in patients with this pathology.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| AP-HP - Hôpital Bichat | Gaël GOUJON, MD | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital La Pitié-Salpêtrière | Jean-Baptiste BACHET, MD | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Saint Antoine | Romain COHEN, MD | Contact (sur clinicalTrials) | |||
| GRPE HOSP DIACONESSES-CROIX ST-SIMON | Olivier DUBREUIL, MD | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Aphp - Hopital Henri Mondor - Créteil - France | Charlotte FENIOUX, MD | Contact (sur clinicalTrials) | |||
| Aphp - Hopital Saint Louis - 75010 - Paris - France | Thomas APARICIO, MD | Contact (sur clinicalTrials) | |||
| Centre Antoine Lacassagne - Nice - France | Contact (sur clinicalTrials) | ||||
| Centre d'Oncologie Saint Yves - 56000 - Vannes - France | Contact (sur clinicalTrials) | ||||
| Centre Hospitalier D'Avignon - 84000 - Avignon - France | Contact (sur clinicalTrials) | ||||
| Centre Hospitalier de Bayeux - 14400 - Bayeux - France | Annie PEYTIER, MD | Contact (sur clinicalTrials) | |||
| Centre Leon Berard - 69008 - Lyon - France | Contact (sur clinicalTrials) | ||||
| Ch de Cahors - Cahors - France | Slim LASSOUED, MD | Contact (sur clinicalTrials) | |||
| Ch de Saint Malo - Saint-Malo - France | Contact (sur clinicalTrials) | ||||
| CH Dr TECHER - 62107 - Calais - France | Fatima MENIAI, MD | Contact (sur clinicalTrials) | |||
| CH Fleyriat - 01000 - Bourg-en-Bresse - France | Patricia PROST, MD | Contact (sur clinicalTrials) | |||
| CH Louis Pasteur - 28630 - Le Coudray - France | David SOLUB, MD | Contact (sur clinicalTrials) | |||
| Ch Perpignan - Perpignan - France | Faiza KHEMISSA, MD | Contact (sur clinicalTrials) | |||
| CHR d'Orléans - 45100 - Orléans - France | Jean-Paul LAGASSE, MD | Contact (sur clinicalTrials) | |||
| Chru de Nancy - 54500 - Vandœuvre-lès-Nancy - France | Marie MULLER, MD | Contact (sur clinicalTrials) | |||
| Chu de Grenoble Alpes - Hopital Michallon - 38700 - La Tronche - France | Contact (sur clinicalTrials) | ||||
| Chu de Reims - 51100 - Reims - France | Olivier BOUCHE, MD | Contact (sur clinicalTrials) | |||
| Chu de Rouen - 76031 - Rouen - France | Contact (sur clinicalTrials) | ||||
| Chu de Tours - 37044 - Tours - France | Romain CHAUTARD, MD | Contact (sur clinicalTrials) | |||
| Chu Dupuytren - 87042 - Limoges - France | Frédéric THUILLIER, MD | Contact (sur clinicalTrials) | |||
| Chu Estaing de Clermont-Ferrand - 63003 - Clermont-Ferrand - France | Marine JARY, MD | Contact (sur clinicalTrials) | |||
| Chu Poitiers - 86021 - Poitiers - France | David TOUGERON, MD | Contact (sur clinicalTrials) | |||
| Chu Rennes Pontchaillou - 35000 - Rennes - France | Géraldine PERKINS, MD | Contact (sur clinicalTrials) | |||
| Grand Hopital de L'Est Francilien - Site de Meaux - Meaux - France | Contact (sur clinicalTrials) | ||||
| Groupe Hospitalier Emile Roux - Le Puy-en-Velay - France | Vanessa PANTE, MD | Contact (sur clinicalTrials) | |||
| Groupe Hospitalier Mutualiste de Grenoble - 38028 - Grenoble - France | Contact (sur clinicalTrials) | ||||
| Hopital Franco-Britannique - 92300 - Levallois-Perret - France | Contact (sur clinicalTrials) | ||||
| Hôpital Privé de la Loire - 42100 - Saint Etienne - France | Contact (sur clinicalTrials) | ||||
| Hôpital privé Jean Mermoz - 69373 - Lyon - France | Pascal ARTRU, MD | Contact (sur clinicalTrials) | |||
| ICANS - 67033 - Strasbourg - France | Meher BEN ABDELGHANI, MD | Contact (sur clinicalTrials) | |||
| Infirmerie Protestante de Lyon - Caluire-et-Cuire - France | Contact (sur clinicalTrials) | ||||
| Institut Bergonie - 33076 - Bordeaux - France | Lola-Jade PALMIERI, MD | Contact (sur clinicalTrials) | |||
| Institut Mutualiste Montsouris - 75014 - Paris - France | Emilie SOULARUE, MD | Contact (sur clinicalTrials) | |||
| Intitut Paoli Calmettes - Marseille - France | Christelle DE LA FOUCHARDIERE, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
1. Men and women aged 18 years or older
2. Histologically confirmed BRAFV600E metastatic colorectal cancer (mCRC),
chemotherapy-naive in the metastatic setting or having initiated a first line of
chemotherapy in the metastatic setting (except encorafenib-cetuximab treatment)
3. Available tumor tissue sample obtained before inclusion with sufficient tissue left
for biological studies. Patients with only fine-needle aspirations are not eligible.
4. Known MMR/microsatellite status (immunohistochemistry [IHC] and polymerase chain
reaction [PCR]) (or under analysis)
5. Patients must have signed a written informed consent form prior to any trial
specific procedures. If the patients are physically unable to give their written
consent, a trusted person of their choice, not related to the investigator or the
sponsor, can confirm in writing the patient's consent.
6. Patients must be willing and able to comply with the study procedures
7. The patient must be affiliated to a social security system or benefit of such a
system.
1. Men and women aged 18 years or older
2. Histologically confirmed BRAFV600E metastatic colorectal cancer (mCRC),
chemotherapy-naive in the metastatic setting or having initiated a first line of
chemotherapy in the metastatic setting (except encorafenib-cetuximab treatment)
3. Available tumor tissue sample obtained before inclusion with sufficient tissue left
for biological studies. Patients with only fine-needle aspirations are not eligible.
4. Known MMR/microsatellite status (immunohistochemistry [IHC] and polymerase chain
reaction [PCR]) (or under analysis)
5. Patients must have signed a written informed consent form prior to any trial
specific procedures. If the patients are physically unable to give their written
consent, a trusted person of their choice, not related to the investigator or the
sponsor, can confirm in writing the patient's consent.
6. Patients must be willing and able to comply with the study procedures
7. The patient must be affiliated to a social security system or benefit of such a
system.
1. Patient with another cancer concomitantly with the mCRC requiring treatment or
influencing the prognosis according to the medical staff.
2. Patients for whom the follow-up will not be assured by the investigator or its team.
3. Any condition that may jeopardize patient participation in the study as well as
non-contraception for men and women with child-bearing potential, and pregnancy or
breast feeding for women.
4. Persons deprived of their liberty or under protective custody or guardianship.